Healthcare stocks fell late Wednesday afternoon with the NYSE Healthcare Index declining 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.
The iShares Biotechnology ETF (IBB) fell 1.8%.
In corporate news, Prenetics Global (PRE) shares dropped 8.7% after the company reported a Q1 loss of $1.36 per diluted share, widening from the loss of $0.80 a year earlier.
Sanofi (SNY) shares fell 2.3%. The company said it will discontinue a phase 3 trial of riliprubart in patients with a type of chronic inflammatory demyelinating polyneuropathy after an interim review found the study was unlikely to provide sufficient efficacy.
Johnson & Johnson (JNJ) was ordered by a Los Angeles jury to pay $32 million to the family of a California woman who died from pleural mesothelioma after alleged exposure to asbestos-contaminated talc, according to the law firm representing the family. Johnson & Johnson shares rose 0.7%.
Pfizer's (PFE) recent share decline has pulled its valuation back toward historical levels, easing some of the concerns raised in its earlier outlook, RBC Capital Markets said. Pfizer's stock fell 0.2%.